Pembrolizumab for advanced cervical cancer: safety and efficacy
Francesca De Felice, Elena Giudice, G. Bolomini, Maria Grazia Distefano, Giovanni Scambia, Anna Fagotti, Cláudia Marchetti
Abstract
: Pembrolizumab may ultimately represent a treatment of choice for advanced cervical cancer with PD-L1 expression, both in metastatic and recurrent setting. However, it is essential to better identify and characterize patients that will benefit the most.
Topics & Concepts
PembrolizumabMedicineOncologyClinical trialInternal medicineCervical cancerCancerDiseaseChemotherapyImmunotherapyCancer Immunotherapy and BiomarkersColorectal and Anal CarcinomasImmunotherapy and Immune Responses